UPMC HEART AND VASCULAR INSTITUTE | UNIVERSITY OF PITTSBURGH | FIND PEOPLE
VMI
 

 

VMI PRESENTERS


Friday, December 2


PRESENTER

TITLE

SESSION #/NAME

TIME

LOCATION

Greg Kato, MD

State of the field: SCD treatment strategies and standards of care

National Marrow Donor Program – Improving Sickle Cell Disease Outcomes Breakfast Symposium

Session Time:
7:30-11:00AM

Presentation Time:
7:40-8:25AM

SD Conv Center
Upper Level
Room 29

         


Saturday, December 3


PRESENTER

TITLE

SESSION #/NAME

TIME

LOCATION

Naomi Gunawardena, BS, PSTP

Aconitase: An Iron Sensing Regulator of Mitochondrial Oxidative Metabolism and Erythropoiesis

102.
Regulation of Iron Metabolism: The Role of Iron in Erythropoiesis Session

Session Time:
9:30-11:00AM

Presentation Time:
9:45AM

Manchester Grand Hyatt
Grand Hall A

Samit Ghosh, PhD

A Novel Role for P-Selectin in the Pathogenesis of Acute Chest Syndrome

113.
Hemoglobinopathies, Excluding Thalassemia—Basic and Translational Science: Mechanisms of Vaso-Occlusion

Session Time:
2:00-3:30PM

Presentation Time:
2:00PM

SD Conv Center
7AB

Maggie Bennewitz, PhD

Lung Vaso-Occlusion in Sickle Cell Disease Mediated By Arteriolar Neutrophil-Platelet Micro-Emboli

113.
Hemoglobinopathies, Excluding Thalassemia—Basic and Translational Science: Mechanisms of Vaso-Occlusion

Session Time:
2:00-3:30PM

Presentation Time:
2:30PM

SD Conv Center
7AB

Chibueze Ihunnah, PhD

Nrf2 Activation Attenuates Hemolysis but Promotes Pulmonary Vascular Dysfunction in Sickle Mice

113.
Hemoglobinopathies, Excluding Thalassemia—Basic and Translational Science: Poster I

Presentation Time:
5:30-7:30PM

SD Conv Center
Hall GH

Maritza Jimenez

Neutrophil-Platelet Aggregation Enables Vaso-Occlusion in Sickle Cell Disease

113.
Hemoglobinopathies, Excluding Thalassemia—Basic and Translational Science: Poster I

Presentation Time:
5:30-7:30PM

SD Conv Center
Hall GH

         


Sunday, December 4


PRESENTER

TITLE

SESSION #/NAME

TIME

LOCATION

Aisha Walker, PhD

Assessing Perceptions of Hydroxyurea Among Sickle Cell Disease Stakeholders Using Social Media

901. Health Services Research—Non-Malignant Conditions: Anemia and Sickle Cell Disease

Session Time:
7:30-9:00AM

Presentation Time:
8:45AM

Manchester Grand Hyatt
Seaport Ballroom EFGH

Seyed Mehdi Nouraie, PhD

Nutritional Status and Hydroxyurea Use Among Children with Sickle Cell Disease in Malawi

114. Hemoglobinopathies, Excluding Thalassemia—Clinical Poster II

Presentation Time:
6:00-8:00PM

SD Conv Center
Hall GH

Cristina Merkhofer, MD

The Impact of Cognitive Function on Adherence to Hydroxyurea Therapy in Patients with Sickle Cell Disease

114. Hemoglobinopathies, Excluding Thalassemia—Clinical Poster II

Presentation Time:
6:00-8:00PM

SD Conv Center
Hall GH

         


Monday, December 5


PRESENTER

TITLE

SESSION #/NAME

TIME

LOCATION

Seyed Mehdi Nouraie, PhD

Hospitalization for Acute Pain in Sickle Cell Disease:  Changes in Clinical Parameters and Factors Predicting Hospital Discharge and Re-Admission

114. Hemoglobinopathies, Excluding Thalassemia—Clinical Poster III

Presentation Time:
6:00-8:00PM

SD Conv Center
Hall GH